Oihana Murillo

Oihana Murillo

Auto-generated profile, based on publicly available information

Oihana Murillo

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NJNancy P. Judd
Nancy P. Judd
AWAshley E. Winkler
Ashley E. Winkler
OMOihana Murillo-Sauca
Oihana Murillo-Sauca
JBJoshua J. Brotman
Joshua J. Brotman
JLJonathan H. Law
Jonathan H. Law
RURavindra Uppaluri
Ravindra Uppaluri
Carcinogen-induced oral cavity squamous cell carcinoma (OSCC) incurs significant morbidity and mortality and constitutes a global health challenge. To gain further insight into this disease, we generated cell line models from 7,12-dimethylbenz(a)anthracene–induced murine primary OSCC capable of tumor formation upon transplantation into immunocompetent wild-type mice. Whereas several cell lines grew rapidly and were capable of metastasis, some grew slowly and did not metastasize. Aggressively growing cell lines displayed ERK1/2 activation, which stimulated expression of CD44, a marker associated with epithelial to mesenchymal transition and putative cancer stem cells. MEK (MAP/ERK kinase) inhibition upstream of ERK1/2 decreased CD44 expression and promoter activity and reduced cell migration and invasion. Conversely, MEK1 activation enhanced CD44 expression and promoter activity, whereas CD44 attenuation reduced in vitro migration and in vivo tumor formation. Extending these findings to freshly resected human OSCC, we confirmed a strict relationship between ERK1/2 phosphorylation and CD44 expression. In summary, our findings identify CD44 as a critical target of ERK1/2 in promoting tumor aggressiveness and offer a preclinical proof–of-concept to target this pathway as a strategy to treat head and neck cancer. Cancer Res; 72(1); 365–74. ©2011 AACR.

8 July 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJune Ho Shin
June Ho Shin
LZLuhua Zhang
Luhua Zhang
OMOihana Murillo-Sauca
Oihana Murillo-Sauca
JKJunmo Kim
Junmo Kim
HKHolbrook E. K. Kohrt
Holbrook E. K. Kohrt
JSJohn B. Sunwoo
John B. Sunwoo
The aryl hydrocarbon receptor (AhR) has become increasingly recognized for its role in the differentiation and activity of immune cell subsets; however, its role in regulating the activity of natural killer (NK) cells has not been described. Here, we show that AhR expression is induced in murine NK cells upon cytokine stimulation. We show that in the absence of AhR, NK cells have reduced cytolytic activity and reduced capacity to control RMA-S tumor formation in vivo, despite having normal development and maturation markers. Although AhR was first identified to bind the xenobiotic compound dioxin, AhR is now known to bind a variety of natural exogenous (e.g., dietary) and endogenous ligands. We show that activation of AhR with an endogenous tryptophan derivative, 6-formylindolo[3,2- b ]carbazole, potentiates NK cell IFN-γ production and cytolytic activity. Further, administration of 6-formylindolo[3,2- b ]carbazole in vivo enhances NK cell control of tumors in an NK cell- and AhR-dependent manner. Finally, similar effects on NK cell potency occur with AhR dietary ligands, potentially explaining the numerous associations that have been observed in the past between diet and NK cell function. Our studies introduce AhR as another regulator of NK cell activity in vivo.

1 February 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
OMOihana Murillo
Oihana Murillo
DLDaniel Moreno Luqui
Daniel Moreno Luqui
CGCristina Gazquez
Cristina Gazquez
DMDebora Martinez-Espartosa
Debora Martinez-Espartosa
INIñigo Navarro-Blasco
Iñigo Navarro-Blasco
GGGloria Gonzalez-Aseguinolaza
Gloria Gonzalez-Aseguinolaza

30 March 2005 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
EFEsperanza Feijoó
Esperanza Feijoó
Carlos AlfaroCarlos Alfaro
Carlos Alfaro
GMGuillermo Mazzolini
Guillermo Mazzolini
PSPatricia Serra
Patricia Serra
IPIvan Penuelas
Ivan Penuelas
IMIGNACIO MELERO
IGNACIO MELERO

1 August 2008 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
IMIGNACIO MELERO
IGNACIO MELERO
OMOihana Murillo
Oihana Murillo
JDJuan Dubrot
Juan Dubrot
SHSandra Hervás-Stubbs
Sandra Hervás-Stubbs
JGJose Luis Perez Gracia
Jose Luis Perez Gracia

26 July 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
OMOihana Murillo-Sauca
Oihana Murillo-Sauca
MCMan Ki Chung
Man Ki Chung
JSJune Ho Shin
June Ho Shin
CKChristina Karamboulas
Christina Karamboulas
SKShirley Kwok
Shirley Kwok
JSJohn B. Sunwoo
John B. Sunwoo
Tumor-initiating cells (TICs) in squamous cell carcinoma of the head and neck (SCCHN) are best characterized by their surface expression of CD44. Although there is great interest in identifying strategies to target this population, no marker of these cells has been found to be functionally active. Here, we examined the expression of the purported marker of normal human oral epithelial stem cells, CD271. We show that CD271 expression is restricted to a subset of the CD44+ cells. Using xenograft assays, we show that the CD44+CD271+ subpopulation contains the most tumorigenic cells. Loss of CD271 function results in a block in the G2-M phase of the cell cycle and a profound negative impact on the capacity of these cells to initiate tumor formation in vivo. Incubation with recombinant NGF results in enhanced phosphorylation of Erk, providing additional evidence that CD271 is functionally active. Finally, incubation of SCCHN cells with antibody to CD271 results in decreased Erk phosphorylation and decreased tumor formation in vivo. Thus, our data are the first to demonstrate that CD271 more specifically identifies the TIC subpopulation within the CD44+ compartment in SCCHN and that this receptor is a functionally active and targetable molecule.